OncoMatch/Clinical Trials/NCT07063875

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

Is NCT07063875 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Aldesleukin for uveal melanoma.

Phase 1/2RecruitingSt Vincent's Hospital, SydneyNCT07063875Data as of May 2026

Treatment: Aldesleukin — A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group. Since recruitment for tebentafusp in metastatic uveal melanoma (mUM) has ended, a new trial is starting to test whether adding IL-2 can help overcome resistance to tebentafusp and improve its effectiveness. This study aims to answer: 1. Can combining tebentafusp with IL-2 improve tumor response and overall survival? 2. What are the benefits and side effects of this combination therapy? All participants will receive both IL-2 and tebentafusp in a 28-day treatment cycle. The dosing schedule is as follows: Cycle1: Day1-3 IL-2 Day4 Tebentafusp Day 10 IL-2 Day 11 Tebentafusp Day 17 IL-2 Day 18 Tebentafusp Day 24 IL-2 Day 25 Tebentafusp Cycle 2 \& thereafter Day 1 IL-2 Day 2 Tebentafusp Day 8 IL-2 Day 9 Tebentafusp Day 15 IL-2 Day 16 Tebentafusp Day 22 IL-2 Day 23 Tebentafusp

Check if I qualify

Extracted eligibility criteria

Cancer type

Melanoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: Tebentafusp (Tebentafusp) — single-agent

RECIST 1.1 defined progression on single-agent Tebentafusp, with no other intervening systemic therapies

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify